Abstract:Breast cancer is the most commonly diagnosed cancer globally and the leading cause of cancer death in women, with ethnic disparities reported in cancer incidence, prognosis, diagnosis and therapeutic response. Although precision oncology holds the promise of revolutionising healthcare, it could exacerbate the racial disparities it seeks to eradicate unless rigorous efforts are made to address research biases. We evaluated the molecular and clinical effects of genetic ancestry in African and South Asian women using a combined cohort of 7,136 breast cancer patients available from four data sources — the 100,000 Genomes Project (UK), The Cancer Genome Atlas (US), the Breast Cancer Now Biobank (London, UK) and Genes & Health (UK). Using patients assigned to the European genetic ancestry as the baseline comparator for all analyses, we find that non-European patients present with breast cancer significantly earlier and die at a younger age. Patients within the African group also have an increased prevalence of higher grade and hormone receptor negative disease. South Asian patients show a small tendency towards lower stage at diagnosis, and a lower tumour mutational burden. We observed significant differences and similarities in the somatic mutational landscape of the non-European populations. Six genes, RBM5, OTOF, FBXW7, NCKAP5, NOTCH3 and GPR158, were differentially mutated across multiple cohorts. Furthermore, potential therapeutic candidates (BRIP1, CDKN2A, CHEK2, FBXW7, GPR158, KDM6A, RET, STK11) were found to be differentially mutated across the African and/or South Asian genetic ancestry groups. Genes with significant differences in germline mutation rates were identified in African and South Asian populations, including those used in current genetic testing (African: TP53, BRCA1, BRCA2, PALB2, p<0.001; South Asian: TP53, BRCA1, BRCA2, p<0.05) as well as those implicated in breast cancer predisposition in the literature, such as CDH1, CDK2A, ERCC3, EPCAM, FANCA, FANCC, POLE and PMS2. There is a higher propensity for BRCAness in the African population, with a lower rate in the South Asian population, serving as a potential prognostic indicator into the response to therapies such as PARP inhibitors. Our study confirms the under-representation of non-European ethnic minority groups within research studies, clinical applications and biobanks, with none of the resources able to recapitulate the ethnic diversity of their representative geographical locations (UK, London and US). Finally, our findings advocate for the implementation of ancestry-specific germline mutation breast cancer screening windows and germline screening panels. This study harnesses multimodal data to improve our understanding of ancestry-associated differences in breast cancer and highlight opportunities to advance health equity in breast cancer thus taking one step closer to achieving the promise of equitable precision oncology.

A global perspective on the ethnic-specific BRCA variation and its implication in clinical application

Ethnic-specific BRCA1/2 Variation Within Asia Population: Evidence from over 78 000 Cancer and 40 000 Non-Cancer Cases of Indian, Chinese, Korean and Japanese Populations.

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Germline Variation In Brca1/2 Is Highly Ethnic-Specific: Evidence From Over 30,000 Chinese Hereditary Breast And Ovarian Cancer Patients

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Ethnic‐specificity, Evolution Origin and Deleteriousness of Asian BRCA Variation Revealed by over 7500 BRCA Variants Derived from Asian Population

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

BRCA1 and BRCA2 Variation in Taiwanese General Population and the Cancer Cohort

Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population

The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry

Ethnic Background and Genetic Variation in the Evaluation of Cancer Risk: A Systematic Review

Prevalence and Spectrum of BRCA Germline Variants in Mainland Chinese Familial Breast and Ovarian Cancer Patients.

Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility

Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area

Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer.

Prevalence of <i>BRCA1</i>/<i>BRCA2</i> pathogenic variation in Chinese Han population

Overview on population screening for carriers with germline BRCA mutation in China

Mutational Analysis of BRCA1 and BRCA2 in Northwest Chinese Breast Cancer Patients.

Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

Clustering of Variations and Haplotype Analysis in the Highly Variable Region of Exon 11 Ofbrca1 in Chinese Women with Sporadic Breast Cancer